LACTOLOGY FOUNDATION

Rimonabant (ATC A08AX01) During Lactation

Rimonabant is an anti-obesity drug classified as ATC A08AX01 and acts as a cannabinoid type 1 (CB1) receptor antagonist/inverse agonist. It should be regarded as incompatible with routine breastfeeding: human milk and infant-exposure data are unavailable, animal data show transfer into milk with possible impairment of suckling, and the medicine was withdrawn or suspended because its psychiatric risks outweighed its benefits.ebi+2

ATC class and general pharmacology

ATC code: A08AX01
International nonproprietary name: Rimonabant
ATC group: A08A — Antiobesity preparations, excluding diet products
Pharmacological subgroup: A08AX — Other antiobesity drugs
Pharmacological class: Selective cannabinoid type 1 receptor antagonist/inverse agonist.ebi+2

Rimonabant was developed as an oral anti-obesity medicine and was marketed in some jurisdictions under the brand name Acomplia. It was intended as an adjunct to calorie-restricted diet and increased physical activity for management of obesity or overweight in people with associated cardiometabolic risk factors.europa

Its anti-obesity activity derives from blockade of CB1 receptors within the endocannabinoid system. CB1 receptors are expressed in central neural pathways involved in appetite, food reward, emotional regulation, motivation, and energy balance, as well as in peripheral metabolic tissues. Endocannabinoid signalling at CB1 receptors normally contributes to appetite stimulation and rewarding food intake; rimonabant reduces this signalling and can consequently reduce hunger, food consumption, and body weight.

Rimonabant is commonly characterized as an inverse agonist, not merely a neutral antagonist. In addition to blocking endocannabinoid-mediated CB1 activation, inverse agonism can reduce the constitutive basal activity of the receptor. This pharmacological property may contribute to both its anorectic effect and its neuropsychiatric toxicity.

After oral administration, rimonabant is rapidly absorbed, with peak plasma concentration generally reached within approximately two hours following a 20 mg dose. It is extensively protein bound in human plasma, undergoes hepatic metabolism involving CYP3A and amidohydrolase pathways, and has a long terminal elimination half-life: approximately 6–9 days in healthy non-obese adults and about 16 days in people with obesity.europa+2

The long half-life is highly relevant to lactation. Even if maternal therapy is stopped, systemic exposure may decline slowly. In the absence of human milk pharmacokinetic data, a short interval between the last dose and resumption of breastfeeding cannot be assumed to eliminate infant exposure.

Toxicological profile

Rimonabant has a clinically important toxicological profile dominated by neuropsychiatric adverse effects. This risk was sufficient to change its regulatory status and is central to any assessment in pregnancy, postpartum care, and lactation.

Reported or clinically relevant adverse effects include:

• Anxiety, nervousness, irritability, agitation, and sleep disturbance.
• Depressed mood, major depressive episodes, emotional lability, and worsening of pre-existing psychiatric illness.
• Suicidal ideation, suicidal behaviour, and completed suicide in reported clinical and post-marketing contexts.
• Nausea, vomiting, diarrhoea, abdominal discomfort, fatigue, dizziness, and headache.
• Reduced appetite and rapid or clinically undesirable weight loss.
• Possible deterioration in maternal sleep, nutritional intake, hydration, and capacity for infant care.

The European Medicines Agency concluded in 2008 that the benefits of rimonabant no longer outweighed its risks and recommended suspension of the marketing authorization for Acomplia throughout the European Union. The review found an approximately two-fold higher risk of psychiatric disorders in patients receiving rimonabant compared with placebo.ema.europa+1

Psychiatric reactions were not limited to patients with a known previous psychiatric disorder. Post-marketing and emerging trial data raised concern that depression, anxiety, sleep disturbances, aggression, and other serious psychiatric effects could occur more frequently in clinical practice than in pre-authorization trials.publications.scot

The CRESCENDO trial, which was terminated after regulatory concerns, did not demonstrate a reduction in major cardiovascular events with rimonabant but was associated with increased anxiety, depression, and suicide risk.nature

Drug-interaction risk is also relevant. Rimonabant metabolism involves CYP3A4, and potent CYP3A4 inhibitors—such as ketoconazole, itraconazole, ritonavir, clarithromycin, telithromycin, nefazodone, and related agents—may markedly increase systemic exposure. In one interaction study, ketoconazole increased rimonabant area under the concentration–time curve by 104%.europa+1

Rimonabant should be considered especially hazardous in people with current or past major depression, suicidal ideation or suicidal behaviour, anxiety disorders, psychosis, bipolar disorder, severe insomnia, substance-use disorder, or other clinically significant psychiatric vulnerability. The early postpartum period is itself a time of increased vulnerability to depression, anxiety, sleep disruption, and severe psychiatric illness; therefore, rimonabant-associated psychiatric toxicity is particularly concerning in a lactating patient.

Lactation pharmacology and infant exposure

There are no adequate published studies measuring rimonabant concentrations in human milk, estimating a relative infant dose, determining milk-to-plasma ratios, measuring infant serum concentrations, or reporting systematically assessed outcomes in breastfed infants.

This lack of evidence does not support a conclusion of safety. Several pharmacological factors create concern:

• Rimonabant is highly lipophilic and distributes extensively into tissues.
• It has a very long terminal elimination half-life, especially in people with obesity.
• It is centrally active and affects neurobehavioural pathways.
• It may persist in maternal tissues and plasma for days after treatment cessation.
• It has potential for severe maternal psychiatric effects that can impair breastfeeding and infant care.europa+2

Animal data are particularly relevant. The European product information stated that rimonabant was detected in the milk of lactating rats and may inhibit suckling. Animal findings cannot quantify human milk transfer or predict a human infant dose precisely, but they provide a biologically plausible warning for a medicine with no human lactation data.europa

If clinically relevant transfer into human milk were to occur, potential infant effects could theoretically include:

• Reduced feeding drive, poor latch, reduced sucking strength, or inadequate milk intake.
• Changes in arousal, sleep pattern, irritability, abnormal crying, or behavioural disturbance.
• Poor weight gain or dehydration secondary to reduced intake.
• Potential effects on neurodevelopmental pathways involving the endocannabinoid system, which has important physiological roles in central nervous system development and feeding regulation.

Because rimonabant may inhibit suckling in animal offspring, particular caution is warranted for newborns, preterm infants, low-birth-weight infants, and exclusively breastfed infants. These children receive a higher milk intake relative to body mass and have immature drug-metabolizing and elimination systems.

Potential indirect effects on lactation are also important. Appetite suppression, nausea, vomiting, diarrhoea, inadequate nutritional intake, rapid weight loss, insomnia, anxiety, and depression may impair milk synthesis, breastfeeding frequency, let-down, maternal responsiveness, and the practical ability to safely care for the infant.

Lactological safety assessment and clinical recommendations

Overall lactological assessment: Avoid; breastfeeding should not be considered compatible with maternal rimonabant therapy.

This recommendation is based on the absence of human milk and infant-outcome data, the long persistence of the medicine, animal evidence of transfer into milk and possible suckling inhibition, the potential for adverse infant neurobehavioural effects, and the well-established maternal psychiatric risk. Regulatory authorities concluded that rimonabant’s overall benefits did not outweigh its risks, leading to suspension of its European Union marketing authorization.europa+1

Clinical recommendations

1. Do not initiate rimonabant during breastfeeding.
   Rimonabant should not be used for postpartum weight reduction or any other indication while breastfeeding is ongoing. This is especially important during exclusive breastfeeding and for newborn, premature, low-birth-weight, or medically fragile infants.
2. Verify current product exposure.
   Rimonabant is no longer routinely available as an authorized anti-obesity medicine in the European Union, but exposure may occur through old supplies, imported products, internet purchases, counterfeit medicines, unregulated “weight-loss” products, or research settings. Establish the exact product, dose, route, dates of use, and all co-exposures.ema.europa+1
3. Do not use a brief feeding interruption as a solution.
   A short pause in breastfeeding, feeding immediately before dosing, or discarding milk for a single day cannot be considered sufficient risk control. Rimonabant has a long elimination half-life—approximately 6–9 days in non-obese individuals and around 16 days in people with obesity—and human milk clearance data are unavailable.ahajournals+1
4. Seek urgent individualized advice after exposure.
   If a breastfeeding patient has taken rimonabant, obtain prompt advice from the prescriber, paediatrician, clinical toxicology service, and specialist medicines-in-lactation service. Decisions about immediate cessation, temporary breastfeeding interruption, milk expression, alternative infant feeding, and timing of possible resumption should be individualized.
5. Prioritize maternal mental-health assessment.
   Screen urgently for depression, anxiety, agitation, sleep disturbance, aggression, suicidal thoughts, suicidal intent, psychotic symptoms, and inability to care safely for the infant. Any suicidal ideation, severe mood change, psychosis, or immediate safety concern requires emergency psychiatric assessment.
6. Monitor the infant after possible exposure.
   Monitor feeding effectiveness, frequency of feeds, wet diapers, weight gain, alertness, sleep, irritability, vomiting, and signs of dehydration. Arrange prompt paediatric assessment for poor feeding, weak suck, lethargy, unusual agitation, persistent vomiting, reduced urine output, poor weight gain, or other acute clinical concerns.
7. Use safer postpartum weight-management alternatives.
   Prefer gradual, nutritionally adequate weight reduction, individualized dietary support, physical activity appropriate to recovery, attention to sleep and mental health, and treatment of obesity-related comorbidities. Pharmacological treatment should be considered only after drug-specific lactation evaluation and a clear assessment of maternal benefit versus infant risk.